Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
MIRA Pharmaceuticals, Inc. - Common Stock
(NQ:
MIRA
)
1.320
+0.060 (+4.76%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
377,013
Open
1.280
Bid (Size)
1.320 (1)
Ask (Size)
1.330 (4)
Prev. Close
1.260
Today's Range
1.230 - 1.337
52wk Range
0.5100 - 5.010
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
November 20, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
October 28, 2024
MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief.
Via
Benzinga
Performance
YTD
+10.92%
+10.92%
1 Month
+23.36%
+23.36%
3 Month
-28.65%
-28.65%
6 Month
+49.15%
+49.15%
1 Year
-59.63%
-59.63%
More News
Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 28, 2024
Via
Benzinga
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
October 28, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
October 25, 2024
Via
Benzinga
Peering Into Mira Pharmaceuticals's Recent Short Interest
September 11, 2024
Via
Benzinga
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
August 26, 2024
Via
ACCESSWIRE
(MIRA) - Analyzing Mira Pharmaceuticals's Short Interest
July 26, 2024
Via
Benzinga
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
October 21, 2024
Via
ACCESSWIRE
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
October 03, 2024
Via
News Direct
Topics
Cannabis
Exposures
Cannabis
Why Mira Shares Are Trading Higher Today
September 27, 2024
Via
Benzinga
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
September 27, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
September 19, 2024
Via
News Direct
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
September 18, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
September 11, 2024
Via
ACCESSWIRE
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
August 27, 2024
Via
News Direct
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
August 26, 2024
Via
Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday
August 26, 2024
Via
Benzinga
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
August 19, 2024
Via
ACCESSWIRE
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
August 12, 2024
Via
ACCESSWIRE
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
August 05, 2024
Via
Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
August 01, 2024
Via
Benzinga
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year
July 29, 2024
Via
News Direct
Topics
Cannabis
Exposures
Cannabis
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.